Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.88 |
| ▸ | LMNA | P02545 | 4/20 | 0.88 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.88 |
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Padimate O SCHEMBL1769139 | 0.94 | ALDH1A1 (1.00) | ALDH1A1CYP3A4LMNAHSD17B10TSHR | |
| Padimate O SCHEMBL29052074 | 0.94 | ALDH1A1 (1.00) | ALDH1A1CYP3A4LMNAHSD17B10TSHR | |
| Padimate O SCHEMBL15432 | 0.94 | ALDH1A1 (1.00) | ALDH1A1CYP3A4LMNAHSD17B10TSHR | |
| Padimate O SCHEMBL28272049 | 0.93 | ALDH1A1 (0.97) | ALDH1A1CYP3A4LMNAHSD17B10TSHR | |
| SCHEMBL1961174 | 0.91 | ALDH1A1 (0.90) | ALDH1A1CYP3A4LMNAHSD17B10TSHR | |
| SCHEMBL20183154 | 0.91 | ALDH1A1 (0.71) | ALDH1A1CYP3A4LMNAHSD17B10TSHR | |
| Padimate O SCHEMBL5246700 | 0.90 | ALDH1A1 (0.93) | ALDH1A1CYP3A4LMNAHSD17B10TSHR | |
| SCHEMBL23607753 | 0.90 | ALDH1A1 (0.70) | ALDH1A1CYP3A4LMNAHSD17B10TSHR | |
| SCHEMBL23607751 | 0.90 | ALDH1A1 (0.70) | ALDH1A1CYP3A4LMNAHSD17B10TSHR | |
| Padimate O SCHEMBL28250616 | 0.89 | ALDH1A1 (0.90) | ALDH1A1CYP3A4LMNAHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2913052-A1 | Phototherapy compositions and methods | OMJ Ireland Limited (PR) | 2015-09-02 | — | — | EP | disclosed |
| EP-1674095-B1 | Phototherapy compositions | OMJ IRELAND LTD (PR) | 2014-08-20 | — | — | EP | disclosed |
| US-8481008-B2 | Phototherapy compositions and methods | THERAKOS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120039825-A1 | PHOTOTHERAPY COMPOSITIONS AND METHODS | MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED (IE) | 2012-02-16 | — | — | US | disclosed |
| US-8057785-B2 | Phototherapy compositions and methods | OMJ IRELAND LIMITED (US) | 2011-11-15 | — | — | US | disclosed |
| US-7244417-B2 | Stabilization of oxidation-sensitive or UV-sensitive active ingredients | BEIERSDORF AG (DE) | 2007-07-17 | — | — | US | disclosed |
| US-7201893-B2 | Stabilization of UV-sensitive active ingredients | BEIERSDORF AG (DE) | 2007-04-10 | — | — | US | disclosed |
| EP-1674095-A1 | Phototherapy compositions | OMJ Ireland Limited (PR) | 2006-06-28 | — | — | EP | disclosed |
| US-20060134031-A1 | Phototherapy compositions and methods | MALLINCKRODT ENTERPRISES LLC | 2006-06-22 | — | — | US | disclosed |
| US-20040247539-A1 | Stabilization of UV-sensitive active ingredients | BEIERSDORF AG | 2004-12-09 | — | — | US | disclosed |
| US-20040247538-A1 | Stabilization of oxidation-sensitive or UV-sensitive active ingredients | BEIERSDORF AG | 2004-12-09 | — | — | US | disclosed |
| US-20040228824-A1 | Cosmetic oil-in-water preparation and use thereof for light skincare | BEIERSDORF AG | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134031-A1 | Phototherapy compositions and methods | VCL, TYR, TTPA | ALDH1A1 1344/4885CYP3A4 2905/4885LMNA 2492/4885 |
| US-20120039825-A1 | PHOTOTHERAPY COMPOSITIONS AND METHODS | VCL, TYR, TTPA | ALDH1A1 1344/4885CYP3A4 2905/4885LMNA 2492/4885 |
| US-20040247539-A1 | Stabilization of UV-sensitive active ingredients | DEGS1, SUCLG1, TPSD1 | ALDH1A1 489/4885CYP3A4 2468/4885LMNA 1238/4885 |
| US-20040247538-A1 | Stabilization of oxidation-sensitive or UV-sensitive active ingredients | DEGS1, CUTA, FASN | ALDH1A1 166/4885CYP3A4 677/4885LMNA 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.